The NM_000152.5:c.883C>A variant in GAA is a missense variant predicted to cause substitution of His by Asn at amino acid 295 (p.His295Asn). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00012 (3/24448 alleles) in the African population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2 (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.716 which is above the thresholds predicting a damaging (>0.7) impact on GAA function (PP3. This variant has been detected in 1 individual with Pompe disease, who was compound heterozygous for the variant and variant c.2560C>T (VCEP Pathogenic) with unknown phase (PMID: 37087815). It has also been detected in 1 individual with low GAA enzyme activity with compound heterozygous for the variant and variant c.1962_1964delAGA; p.Glu655del (VCEP Pathogenic) with unknown phase (Clinical lab data), thus met PM3. At least 2 patient with this variant had documented GAA activity in blood (PMID: 37087815; clinical lab), meeting PP4_Moderate. There is a ClinVar entry for this variant (Variation ID: 953728). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PM2_supporting, PP3, PM3, PP4_moderate. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 19, 2024)